Pfizer Aims $2.5 Billion in Extra Cost Reductions After Exceeding Earnings Projections

Strong demand for the blood thinner Eliquis and recently acquired medications drove Pfizer’s (PFE.N) better-than-expected second-quarter results, which were released on Tuesday. The company also revealed plans to slash costs by an additional $2.5 billion.

In an effort to counteract diminishing COVID-related revenue and reestablish sustainable development, the New York-based pharmaceutical company anticipates $9.7 billion in total net savings from its cost reductions through 2029.

Investors are watching for indications that the company’s $10 billion acquisition of Metsera can help establish a significant foothold in the rapidly expanding obesity market, which some analysts predict will reach $150 billion annually in the next ten years. The company is counting on newer medications to reduce its reliance on outdated blockbuster drugs.

Pfizer has stated that it anticipates resuming faster growth after 2028. Its stock increased by 2.3%.

In an interview, CEO Albert Bourla stated that while the company’s reorganization initiatives reduced administrative, sales, and marketing costs by 3% in the first half of the year, research and development expenditures increased by 12% annually.

We reinvest in R&D and are generating efficiency, especially in enabling operations like finance, legal, and HR,” Bourla stated.

According to him, the corporation has already taken significant M&A decisions in sectors like obesity and cancer. According to him, Pfizer will now concentrate on smaller bolt-on purchases across a variety of therapeutic areas and has about $6 billion of dealmaking capability left.

According to Bourla, Pfizer intends to continue raising its dividend after resolving a number of impending patent expirations.

Dave Denton is scheduled to leave the company later this month, therefore it is looking for a new chief financial officer.

According to RBC Capital analyst Trung Huynh, Pfizer needs to deliver on important catalysts through 2026 in order to be perceived once more as a growth firm rather than solely as a restructuring tale, even though the earnings beat demonstrated broad-based resilience across the portfolio.